Iq-ai Ltd Regulatory News (IQAI)

8 September 2023

IQ-AI Ltd

("IQ-AI" or the "Company")

Reduced Gadolinium Approach Validated with IB Neuro on 1.5T MR Scanners

Imaging Biometrics, LLC (IB), a wholly owned subsidiary of IQ-AI Ltd (LSE: IQAI), is pleased to announce the results of a study that validates IB Neuro's processing of reduced-dose gadolinium-based contrast agent (GBCA) perfusion studies on 1.5T scanners.

The multi-center study, led by Dr. Mark Shiroishi, MD, Assistant Professor of Neuroradiology and Director of Neuro-Oncology Imaging at the Keck School of Medicine of USC, is an extension of the foundational study published in April 2019 (Moving Towards a Consensus DSC-MRI Protocol: Validation of A Low Flip Angle Single Dose Option as a Reference Standard for Brain Tumors) that validated the use of a low-dose protocol for acquiring MRI perfusion data. In the 2019 study, it was shown that 3T MRI data collected with 50% less GBCA could provide perfusion maps comparable to the higher dose standard when processed using IB Neuro.

IB Neuro has now been validated using this approach on 1.5T scanners.

Dynamic susceptibility contrast (DSC) MRI is the most common approach used to measure brain tumor perfusion. Relative cerebral blood volume (rCBV) is the most widely generated parameter map that provides important information regarding tumor grade, prognosis, and treatment response. IB Neuro automatically processes DSC data using its unique contrast leakage (of GBCA) correction technology. It is the only platform that generates quantitative output that can be directly compared across timepoints. This study also makes IB Neuro the only platform proven to provide accurate perfusion maps under low-dose conditions at both 1.5T and 3T MR scanners.

"IQ-AI and our collaborators around the world continue to make advancements towards reducing GBCA consumption," said Trevor Brown, CEO of IQ-AI. "While our patented artificial intelligence technology available in IB Zero G remains in active development, this study provides an immediate option for cutting GBCA by 50% on 1.5T and 3T scanners", Brown added.

"The study demonstrates that a single dose (no preload), low flip angle method does not compromise image quality," said Dr. Mark Shiroishi, MD. "This is a great added benefit for patients who may have concerns about GBCA risks, and for administrators looking for opportunities to curtail operational expenses".

--ENDS-

The Directors of the Company accept responsibility for the contents of this announcement.

For further information, please contact:

About Imaging Biometrics® LLC: IB is a wholly owned subsidiary of IQ-AI Limited, (LON: IQAI) (OTCQB: IQAIF) and focuses on delivering quantitative imaging platforms and therapeutics that transform how clinicians diagnose and treat patients more efficiently and effectively. For more information about Imaging Biometrics, visit the company's website at www.imagingbiometrics.com. Follow IB on Twitter, @IQAI_IB.